These patterns persisted upon further stratification, with CLDN8 expression not serving as a significant predictor of DFS in patients with triple-negative breast cancer (p = 0.55) (Figure 1G), ER(−)/HER2(+) (p = 0.719) (Figure 1H), or ER(+)/HER2(−) (p = 0.463) (Figure 1I). The gene discussed is CLDN8; the disease is triple-negative breast carcinoma.